诺和诺德与 Metaphore Biotechnologies 合作，利用 Metaphore 的 MIMIC™ 平台和 GLP-1R 靶向性开发两种价值 6 亿美元的肥胖症治疗方法。 Novo Nordisk partners with Metaphore Biotechnologies to develop up to two obesity treatments worth $600M, using Metaphore's MIMIC™ platform and GLP-1R targeting.

诺和诺德与 Flagship 旗下 Metaphore Biotechnologies 合作开发多达两种先进的肥胖症治疗方法，潜在支付额高达 6 亿美元。 Novo Nordisk partners with Flagship's Metaphore Biotechnologies to develop up to two advanced obesity treatments, with potential payments reaching $600M. Metaphore 的 MIMIC™ 平台将用于针对多个肥胖相关目标，包括胰高血糖素样肽 1 受体 (GLP-1R)。 Metaphore's MIMIC™ platform will be applied to target multiple obesity-related targets, including the glucagon-like peptide 1 receptor (GLP-1R). 此次合作旨在研发可扩展且疗效更持久的肥胖症治疗药物。 The collaboration aims to create scalable drugs with longer-lasting effects for obesity treatment.